<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129893">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01411046</url>
  </required_header>
  <id_info>
    <org_study_id>GCR-RA-CSI</org_study_id>
    <nct_id>NCT01411046</nct_id>
  </id_info>
  <brief_title>Difference in GC-induced Adrenal Insufficiency in RA Related to Polymorphisms in the Glucocorticoid Receptor Gene</brief_title>
  <official_title>Observational Cohort Study on Difference in Glucocorticoid-induced Adrenal Insufficiency in Patients With Rheumatoid Arthritis Related to Different Sensitivity Polymorphisms in the Glucocorticoid Receptor Gene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Development of glucocorticoid (GC)-induced adrenal insufficiency is a serious adverse effect
      of GC treatment. It is today not possible to predict this adverse effect. The project aims
      at investigating a possible individual aspect, which may render subjects more or less
      sensitive to glucocorticoids, and thereby influence development of GC induced adrenal
      insufficiency. The hypothesis is that subjects with one or another of the polymorphisms in
      the GC receptor gene will either have increased or diminished GC sensitivity. This may be
      responsible for differences in development of GC induced adrenal insufficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood is sampled from 200 pts with rheumatoid arthritis (RA), fulfilling the inclusion
      criteria and their GR haplotypes will be determined by polymerase chain reaction (PCR). 2 x
      25 patients with the interesting GR polymorphisms, and these will be included for a
      Synacthen test of their adrenal function. Information from the results of the study will be
      able to assist clinicians to identify patients at risk and thus individualize GC therapy in
      a tailored fashion. Results of the study will be important for all patient groups worldwide
      on GC therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>adrenal insufficiency</measure>
    <time_frame>upon first visit within average 1 month</time_frame>
    <description>test for adrenal function by stimulation test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>upon inclusion (baseline)</time_frame>
    <description>test by questionnaires</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>RA treated with glucocorticoid</arm_group_label>
    <description>50 pts with RA</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>RA treated with glucocorticoid</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples and DNA from gene analyses
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        50 consecutive patients with rheumatoid arthritis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients &gt; 18 years)

          -  Caucasian classified with rheumatoid arthritis.

          -  1987 ACR-classification criteria.

          -  Prednisolone min 5mg/day for at least 6 months.

          -  Presence of either BclI (high GC sensitivity) or 9Î² (low GC
             sensitivity)polymorphisms.

        Exclusion Criteria:

          -  Other major organ disease

          -  Endocrine disease

          -  Active infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulla Feldt-Rasmussen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ulla Feldt-Rasmussen, Professor</last_name>
    <phone>+45 35451023</phone>
    <email>ufeldt@rh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulla Feldt-Rasmussen, Professor</last_name>
      <phone>+4535451023</phone>
      <email>ulla.feldt-rasmussen@dadlnet.dk</email>
    </contact>
    <investigator>
      <last_name>Ulla Feldt-Rasmussen, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 16, 2016</lastchanged_date>
  <firstreceived_date>July 28, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Ulla Feldt-Rasmussen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Glucocorticoid</keyword>
  <keyword>polymorphism</keyword>
  <keyword>Glucocorticoid receptor gene</keyword>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>adrenal insufficiency</keyword>
  <keyword>prednisolone treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Adrenal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucocorticoids</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
